Clopidogrel

CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population

Y. M. Guo, Zhao, Z. C., Zhang, L., Li, H. Z., Li, Z., Sun, H. L., Guo, Y. M., Zhao, Z. C., Zhang, L., Li, H. Z., Li, Z., and Sun, H. L., “CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population”, vol. 15, p. -, 2016.

The goal of this study was to explore the polymorphisms of CYP2C19 (CYP2C19*2, CYP2C19*3) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) on clopidogrel therapy in Zhengzhou city for guidance on clinical medication and reduction in the incidence of thromboembolic events. Two hundred and thirty-four ACS patients undergoing PCI were included in the study, including 171 males (average age = 64.13 ± 12 years) and 63 females (average age = 67.86 ± 10.20 years).

Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers

Y. G. Yang, Zhang, M., Jiang, N., Song, L. X., Xu, X. T., Di, X. H., Xu, L., Xu, J., and Zhao, G. T., “Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers”, vol. 14, pp. 16736-16743, 2015.

We aimed to evaluate the bioequivalence of clopidogrel in healthy Chinese volunteers after administration of a single oral dose. We administered a single oral dose of 75 mg clopidogrel (test and reference) to 32 healthy Chinese volunteers according to an open, randomized, crossover design. The concentration of clopidogrel acid (carboxylic metabolite of clopidogrel) in the plasma was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients

B. Sun, Li, J., Dong, M., Yang, L., Wu, C., Zhu, L., and Cong, Y. L., “Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients”, vol. 14, pp. 1434-1442, 2015.

We investigated the correlation between genetic polymorphisms of cytochrome P450 enzyme genes and the outcome of clopidogrel treatment in 118 coronary disease patients after percutaneous coronary intervention at the Chinese PLA General Hospital. Patients were divided into an ischemia event relapse group (IERG) and a non-IERG group (NIERG) based on relapse of ischemia events within 6 months after percutaneous coronary intervention. Ischemia occurred in 26.27% of patients.

Pharmacogenomics: accessing important alleles by imputation from commercial genome-wide SNP arrays

R. Liboredo and Pena, S. D. J., “Pharmacogenomics: accessing important alleles by imputation from commercial genome-wide SNP arrays”, vol. 13, pp. 5713-5721, 2014.

Personalized medicine is becoming a medical reality, as important genotype-phenotype relationships are being unraveled. The availability of pharmacogenomic data is a key element of individualized care. In this study, we explored genotype imputation as a means to infer important pharmacogenomic alleles from a regular commercially available genome-wide SNP array. Using these arrays as a starting point can reduce testing costs, increasing access to these pharmacogenomic data and still retain a larger amount of genome-wide information.

Subscribe to Clopidogrel